Associated Genetic Biomarkers
NCI Definition: A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos. 
Mesotheliomas most frequently harbor alterations in BAP1, NF2, CDKN2A, CDKN2B, and TP53 .
CDKN2A Loss, CDKN2B Loss, BAP1 Mutation, BAP1fs, and NF2 Mutation are the most common alterations in mesothelioma .
There are 29 clinical trials for mesothelioma, of which 23 are open and 6 are completed or closed. Of the trials that contain mesothelioma as an inclusion criterion, 20 are phase 1 (15 open), 4 are phase 1/phase 2 (3 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open).
Deficient, HLA-A*02:01, and MLH1 are the most frequent gene inclusion criteria for mesothelioma clinical trials .
Pembrolizumab, cisplatin, and durvalumab are the most common interventions in mesothelioma clinical trials.
Significant Genes in Mesothelioma
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.